Sort   by:  
 Page size 
Transcriptomicssingle cell RNAseq of memory B cells in the context of rituximab-treated ITP patients
Rituximab (RTX) is widely used as a first-line therapeutic strategy in B cell-mediated autoimmune diseases. However, a large proportion of patients either do not respond to the treatment or relapse during B cell reconstitution. Primary immune thrombocytopenia (ITP) is a prototypic B cell mediated au...
ORGANISM(S): Homo sapiens 
2021-01-31 | E-MTAB-9955 | biostudies-arrayexpress
TranscriptomicsAntibody mRNA-seq repertoire sequencing to study relapses after B-cell depletion therapy
Rituximab (RTX) is widely used as a first-line therapeutic strategy for patients affected by immune thrombocytopenia (ITP). However, a large proportion of patients relapse after successful treatment. The present NGS assay was done to help find the cause for this relapse on the immune repertoire leve...
ORGANISM(S): Homo sapiens 
2021-01-18 | E-MTAB-9953 | biostudies-arrayexpress
TranscriptomicsMatthieuMAHEVAS
Splenic tissues from immune thrombocytopenia purpura (ITP) patients splenectomized after primary failure of treatment with the B-cell depleting agent rituximab were analyzed, and antibody-secreting cells were identified as the major B-cell population resisting the treatment. The phenotype, antibody ...
ORGANISM(S): Homo sapiens 
2013-08-08 | E-MEXP-3711 | biostudies-arrayexpress
UnknownCOVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
Not available
S-EPMC7993930 | biostudies-literature
UnknownCOVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI - the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases.
Not available
S-EPMC9091487 | biostudies-literature
Sort   by:  
 Page size